We are live on ! Find out more
IMDX

Insight Molecular Diagnostics

30 hedge funds and large institutions have $49.2M invested in Insight Molecular Diagnostics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more capital invested

Capital invested by funds: $20M → $49.2M (+$29.2M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

11% more funds holding

Funds holding: 2730 (+3)

6.29% more ownership

Funds ownership: 49.97%56.27% (+6.3%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
30
Holders Change
+3
Holders Change %
+11.11%
% of All Funds
0.4%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
8
Increased
9
Reduced
6
Closed
5
Calls
Puts
Net Calls
Net Calls Change

IMDX Hedge Fund Activity: Q1 2025 in Review

30 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2025, worth a combined $49.2M — up 146% from $20M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new IMDX positions and 5 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.

The largest buyer was Broadwood Capital, adding an estimated $14M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $31.5K sold.

  • 30 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2025, up from 27 in Q4 2024.
  • Funds reported $49.2M of Insight Molecular Diagnostics stock for Q1 2025, up 146% quarter-over-quarter.
  • 8 funds opened new Insight Molecular Diagnostics positions in Q1 2025 and 5 closed out, a net change of +3 holders.
  • The largest Insight Molecular Diagnostics buyer in Q1 2025 was Broadwood Capital, an estimated $14M added.
  • The largest Insight Molecular Diagnostics seller in Q1 2025 was Two Sigma Securities, an estimated $31.5K sold.

Based on aggregated 13F filings for Q1 2025.